ulf, you make good sense........................................................
Simple fact; the SEC granted market makers the the ability to trade the very stocks they make a market for.
RXI would know through RXI's transfer agent who sells and who bought those shares.
Herein lies the problem; there is nothing ( that I can think of ) that RXI or any other company can do to prevent this activity. In the first place it is legal. Secondly, RXI cannot divulge to anyone who it is that is buying or selling shares in the company, for obvious reasons. No more than any of us would like our stock trades made public.
You can thank the SEC, and our government for allowing this activity which in my opinion is borderline criminal, no, just plain criminal. Inept government at its finest.
Not long ago MM's were not allowed to do this. How and why they were given this authority is beyond me.
So, I believe this is partly the reason RXI did the spit to get us on nasd. All bases were supposedly covered to uplist until nasd discovered a certain financing RXI placed earlier in the year, then nasd nixed the uplist until the stock began trading over $4.00. This was told to me directly by the company.
So, company's progress is stellar IMO, all on target, news today further confirming both safety and efficacy for a drug into Ph2 trials with a $4-5 B market potential, a well seasoned management team second to none, funding through Ph2, and a promising pipeline upcoming. But the stock is dead in its tracks.
For the life of me, I cannot think of other reasons why, but I'd certainly like to hear your views as to why...
a good evening All..............
judging by the continuous pattern. very low float not lot of free trading shares. easy for them to keep the price down,, after all they make the market for this stock................should be a law against it, trading the socks that they make the market for. SEC at its finest.
Look how long it took them to bag Bernie..............................
stockwatcher, all good news this morning, no significant safety issue, while showing further reduction. Will fine tune the Ph2 trials also. All good.
Why no stock movement? bothersome to all here............
Let's see if anything significant comes out of Piper Jaffrey conference today. They are very effective in getting a company's word out. Good luck All
Bio, I must correct you in that the topical medications available do not "handle the problem" of over scarring. some bay tighten skin to give that appearance but there is nothing that will actually diminish a scar. All like Oculus' new drug are for pain and itch...........
I am not aware of a compound on the market that can reduce a scar to any magnitude.
Please correct me if I am mistaken here......good luck All
who on this board would thumbs down my post above if they were not attempting to bash here?
And if you real all of this mornings posts you may also have an idea just who they are...good luck All
It is a medication for the relief of pain and itching, and was approved as such. Because the company claims that it reduces scarring is another matter. If their drug has those qualities why were they not put through proper testing for that approval.
They are claiming that in addition to its intended use, it may also reduce scarring.
In addition, RXI-109 is for use in planned surgeries to inhibit over scarring.
wrong time perhaps, but of no fault of the company. It appeared they were all clear to uplist until nasd found a certain financing RXI did early in the year nixed it. nasd then required a trading level above $4.00 to list.
This was told to me by IR 2-3 months ago.......
smokey, just some scare tactic bashing. Oculus drug is for pain and itching.
But it did seem to get a few on this board rattled.............ps. notice my thumbs down. too funny...
By Everdeen Mason
Oculus Innovative Sciences Inc. (OCLS) said it received approval from the U.S. Food & Drug Administration for its scar medication, Microcyn Scar Management Hydrogel, and it should go on the market next year.
Oculus shares more than doubled to $6.02 in premarket trading from Tuesday's close of $2.33.
The company conducted a study that showed the medication--meant to treat hypertrophic and keloid scarring from burns, general surgical procedures and trauma wounds--improved itching and pain relief in keloid scars.
Quite a different purpose..................good luck All
rxi-109 decreases scarring during the wound healing process or through scar revision surgery by up to 50%. It is not a topical cream as Oculus' treatment which claims to reduce an existing scar.
There are many topical compounds that claim to diminish a scar. RXI limits the scarring at the outset in planned surgeries......................good luck All
to expand on the benefits, usefulness, and scope of market of rxi-109 as opposed to simply reporting on the trial results. I think they could use a little PR assistance.
Just my thought this morning. good luck All
fearing, rxi-109 decreases scarring during the wound healing process or through scar revision surgury by up to 50%. It is not a topical cream as Oculus' treatment which claims to reduce an existing scar.
There are many topical compounds that claim to diminish a scar. RXI prevents them from forming................good day All
what kind of a board is this, don't even want to advance dialogue on the company?
not concerned I guess............good luck all................
guess nobody invested in this company knows of this. Or perhaps aren't concerned........good luck All.........